- The acquisition will expand Medtronic’s capabilities to serve people using multiple daily injections (MDI) to manage diabetes with the addition of Companion Medical’s InPen to Medtronic’s portfolio. The acquisition is expected to be closed within 1-2mos.
- Medtronic will advance the automation of insights and dosing capabilities to reduce the burden of diabetic patients. Additionally, Medtronic will expand the availability of InPen globally
- InPen is the only US FDA-cleared smart insulin pen system paired with an integrated diabetes management app for providing support to diabetic patients regardless of how insulin is delivered
Click here to read full press release/ article | Ref: Medtronic | Image: Diabetes Daily